Abbott reports fourth-quarter sales that miss analysts’ estimates.

Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...

Abbott Laboratories raised its dividend 7% and targets $5.80 EPS with 19.2x forward P/E and double-digit profit growth. See ...

Abbott Labs stock drops on sales miss and weak guidance for 2026, analyst cuts price target but maintains rating.

Abbott missed analysts’ profit expectations for Q4 2025, yet the company’s full year financials were buoyed by strong ...

Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, ...

Abbott Laboratories' (NYSE: ABT) January 2026 price pullback is making its stock look attractively valued. The move, driven ...

Abbott Laboratories stock has reached a 52-week low, closing at $107.27. This marks a notable point for the healthcare company, as it navigates a challenging market environment. Over the past year, ...

Abbott shares sank 8% as Q4 revenue of $11.5B missed the $11.8B target, with nutrition sales dropping 8.9% on price ...

Abbott Laboratories fell on its latest earnings report, but I view this as a buying opportunity. Read the latest analysis on ...

Abbott Laboratories (NYSE:ABT) is included among the 12 Most Profitable Dividend Stocks to Buy in 2026. On January 23, ...